# Phase 2 cholangiocarcinoma trials recruiting: 69 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 69 trials in phase 2 for cholangiocarcinoma that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 cholangiocarcinoma trials: 69 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/cholangiocarcinoma

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 69
- Recruiting or not yet: 69
- Read on: November 19, 2026

## Trials

The 25 newest of 69, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 7, 2026 | NCT07862998 | A Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Advanced/Metastatic or Surgically Unresectable... | Incyte Corporation | Phase 2 | Not yet recruiting | Unresectable Cholangiocarcinoma, Advanced/Metastatic Cholangiocarcinoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07862998) |
| September 29, 2026 | NCT07847710 | Perioperative Retlirafusp Alfa(Anti-PD-L1/TGF-β Bifunctional Fusion Protein) Plus Famitinib and GEMOX-Based Hepatic Arterial Infusion... | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma (Icc), Neoadjuvant Therapy | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07847710) |
| September 29, 2026 | NCT07846267 | Cryoablation Combined With Anlotinib Plus TQB2868 in Patients With Advanced Intrahepatic Cholangiocarcinoma | Fudan University | Phase 2 | Not yet recruiting | Intrahepatic Cholangiocarcinoma | 56 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07846267) |
| September 25, 2026 | NCT07841574 | HAIC Plus QL1706 & Bevacizumab in Unresectable HER2-Negative ICC | Sponsor not shown (see the record) | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841574) |
| August 28, 2026 | NCT07793253 | Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | Not yet recruiting | Biliary Tract Cancers, Intrahepatic Cholangiocarcinoma (Icc), Extrahepatic Cholangiocarcinoma, Gallbladder Carcinoma... | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793253) |
| August 24, 2026 | NCT07780838 | Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma | Ohio State University Comprehensive Cancer Center | Phase 2 | Recruiting | Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Extrahepatic... | 29 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07780838) |
| August 14, 2026 | NCT07766187 | Combination Therapy Using Durvalumab and Histotripsy for Treatment of Intrahepatic Cholangiocarcinoma | University of Wisconsin, Madison | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07766187) |
| July 28, 2026 | NCT07729917 | Precision Integrated Strategies and Efficacy Evaluation for Biliary Tract Cancers: An Umbrella Platform Study | Zhejiang University | Phase 2 | Not yet recruiting | Bile Duct Carcinoma, Cholangiocarcinoma | 240 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729917) |
| June 29, 2026 | NCT07673341 | \[18F\]FTT Positron Emission Tomography/Computed Tomography to Predict Treatment Response in Patients Scheduled to Receive Gemcitabine... | University of Washington | Phase 2 | Recruiting | Cholangiocarcinoma | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07673341) |
| June 9, 2026 | NCT07636824 | Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A... | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Recruiting | Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07636824) |
| June 3, 2026 | NCT07623642 | A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or... | GV20 Therapeutics | Phase 2 | Not yet recruiting | Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and... | 227 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623642) |
| May 6, 2026 | NCT07570849 | Chidamide Combined With Chemotherapy and Immunotherapy as First-line Treatment for Advanced Intrahepatic Cholangiocarcinoma | Shanghai Zhongshan Hospital | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570849) |
| May 1, 2026 | NCT07561775 | Adebrelimab Plus S-1 for Resected Cholangiocarcinoma | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Cholangiocarcinoma, Biliary Tract Cancer | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07561775) |
| April 13, 2026 | NCT07522476 | A Clinical Study to Evaluate the Efficacy and Safety of VG2025 in Intrahepatic Cholangiocarcinoma | Virogin Biotech Ltd. | Phase 2 | Recruiting | Intrahepatic Cholangiocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522476) |
| April 7, 2026 | NCT07514533 | The Efficacy and Safety of Pucotenlimab (PD-1) Combined With Becotatugvedotin (EGFR-ADC) in Advanced Cholangiocarcinoma | Sir Run Run Shaw Hospital | Phase 2 | Not yet recruiting | Cholangiocarcinoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07514533) |
| March 17, 2026 | NCT07478523 | FAPI-PET Value for the Initial Screening of Pancreatic and Biliary Cancers | University Hospital, Bordeaux | Phase 2 | Recruiting | Cholangiocarcinoma, Pancreatic Adenocarcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07478523) |
| February 25, 2026 | NCT07432568 | A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC | Tianjin Medical University Cancer Institute and Hospital | Phase 2 | Not yet recruiting | Intrahepatic Cholangiocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07432568) |
| January 20, 2026 | NCT07353827 | FOLFOX-HAIC Combined With Donafenib and Pucotenlimab as First-Line Treatment for Unresectable Intrahepatic Cholangiocarcinoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Intrahepatic Cholangiocarcinoma (Icc), Hepatic Arterial Infusion Chemotherapy | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07353827) |
| December 22, 2025 | NCT07296666 | Adjuvant Chemotherapy for BTC Based on 3D-PTA | Fudan University | Phase 2 | Not yet recruiting | Cholangiocarcinoma | 98 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07296666) |
| December 15, 2025 | NCT07282912 | Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut... | Yale University | Phase 2 | Recruiting | Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma, Pancreas... | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07282912) |
| December 3, 2025 | NCT07260175 | Phase II Study Evaluating Ivosidenib Maintenance After SOC Adjuvant Chemotherapy in Curative mIDH1 Cholangiocarcinoma | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 | Recruiting | Cholangiocarcinoma, IDH Mutation | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07260175) |
| October 31, 2025 | NCT07223307 | REGULUS: MRI-guided Adaptive SABR for Liver Cancers | Stanford University | Phase 2 | Recruiting | Liver Cancer, Intrahepatic Cholangiocarcinoma, Liver Metastases, HCC | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07223307) |
| October 1, 2025 | NCT07201519 | Study of Safety/Feasibility of a Hybrid Model of Tertiary and Community Delivery of Hepatic Artery Infusion Chemotherapy | Sponsor not shown (see the record) | Phase 2 | Recruiting | Colorectal Cancer Metastatic, Intrahepatic Cholangiocarcinoma | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07201519) |
| August 17, 2025 | NCT07128290 | PErioperative CISGEM + Rilvegostomig in High-Risk Resectable Intra Hepatic CholangioCarcinoma | Federation Francophone de Cancerologie Digestive | Phase 2 | Not yet recruiting | Intrahepatic Cholangiocarcinoma (Icc) | 49 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128290) |
| August 6, 2025 | NCT07105852 | Exploring the Safety and Efficacy of Sacituzumab Tirumotecan Combined With Pucotenlimab in the Treatment of Advanced Cholangiocarcinoma | Sir Run Run Shaw Hospital | Phase 2 | Recruiting | Cholangiocarcinoma | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07105852) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Fudan University | 6 |
| The First Affiliated Hospital with Nanjing Medical University | 3 |
| Tianjin Medical University Cancer Institute and Hospital | 3 |
| Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 2 |
| National Cancer Institute (NCI) | 2 |
| Shanghai Zhongshan Hospital | 2 |
| Sir Run Run Shaw Hospital | 2 |
| West China Hospital | 2 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2 |
| Zhejiang University | 1 |
| Eastern Hepatobiliary Surgery Hospital | 1 |
| Harbin Medical University | 1 |
| National Cancer Institute, Naples | 1 |
| Ohio State University Comprehensive Cancer Center | 1 |
| Oslo University Hospital | 1 |
| Virogin Biotech Ltd. | 1 |
| University Hospital, Bordeaux | 1 |
| Nanfang Hospital, Southern Medical University | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| Australasian Gastro-Intestinal Trials Group | 1 |
| Stanford University | 1 |
| [Beijing InnoCare Pharma Tech Co., Ltd.](https://specstream.ai/data/clinical-trials/company/beijing-innocare-pharma-tech-co-ltd) | 1 |
| Third Affiliated Hospital, Sun Yat-Sen University | 1 |
| University of Wisconsin, Madison | 1 |
| Sun Yat-sen University | 1 |

## By country

| Country | Trials |
| --- | --- |
| China | 36 |
| United States | 16 |
| Italy | 4 |
| France | 4 |
| Germany | 3 |
| Australia | 3 |
| Netherlands | 3 |
| Norway | 2 |
| Canada | 2 |
| South Korea | 2 |
| Spain | 2 |
| United Kingdom | 2 |
| Taiwan | 1 |
| Argentina | 1 |
| Brazil | 1 |
| Hong Kong | 1 |
| Japan | 1 |
| Poland | 1 |
| Portugal | 1 |
| Sweden | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Drama schools in the United States](https://specstream.ai/data/businesses/drama-schools/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Hong Kong style cafes in the United States](https://specstream.ai/data/businesses/hong-kong-style-cafes/united-states)
- [Latin American restaurants in the United States](https://specstream.ai/data/businesses/latin-american-restaurants/united-states)
- [Neuropathology practices in the United States](https://specstream.ai/data/businesses/neuropathology-practices/united-states)
- [Poke restaurants in the United States](https://specstream.ai/data/businesses/poke-restaurants/united-states)
